During the past 7 years the UCCRC Flow Cytometry Facility has been under the direction of Dr. Jeffrey Bluestone. He has been responsible for the overall growth and direction of the facility. In 1993, Ms Julie Auger joined the facility as Technical Director. Her extensive experience in flow cytometry elevated the quality and extent of the services resulting in more than a doubling of the use of the Facility since her arrival. The facility now provides advanced technologies to basic and clinical researchers and extensive support to all cancer members. During the past year, there has been a growing need for centralized immunohistochemistry and in situ services for cancer center members. A recent survey showed that more than 25 cancer center members expressed strong interest in developing an immunohistochemistry core. To that end, the Flow Cytometry Facility had begun to provide limited immunohistochemistry services to fill this increasing need. This has been possible due to the common use of many reagents for both flow cytometry and immunohistochemistry and our ability to link these two approaches to answer research questions. More recently, the University of Chicago has been fortunate to have recruited Dr. David Baunoch to the Department of Pathology. Dr. Baunoch is a well established pathologist with a strong background in both immunohistochemistry and in situ analyses. He has agreed to lead the immunohistochemistry /in situ component of the core and establish a first-rate facility for cancer center use. The addition of these technologies to the UCCRC Flow Cytometry Core will provide a state-of- the-art facility for broad-based research in immunophenotyping, DNA/cell cycle analysis, and apoptosis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-25
Application #
6268780
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
25
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications